The phase 3 TRIUMPH-4 data showed these rates at 9 mg and 12 mg doses respectively: Nausea: 38.1% and 43.2% (vs 10.7% placebo) Diarrhea: 34.7% and 33.1% (vs 13.4% placebo) Constipation: 21.8% and 25.0% (vs 8.7% placebo) Vomiting: 20.4% and 20.9% (vs placebo) These numbers are higher than cagrilintide monotherapy across the board
Protein is super important on GLP-1 because it helps keep you full and satisfied for longer, preventing those hunger pangs that can lead to overeating
W., Hu, J., Morioka, T., Duttaroy, A., Burkey, B., & Kulkarni, R
Its shorter duration of action more closely mimics the pulsatile nature of endogenous GHRH secretion, thereby supporting physiological episodic GH release patterns in contrast to CJC-1295 with DAC, which produces sustained GH elevation with days-long GHRH-receptor occupancy